10.11
-0.005(-0.05%)
Currency In USD
| Previous Close | 10.11 |
| Open | 10.11 |
| Day High | 10.14 |
| Day Low | 10.1 |
| 52-Week High | 18.13 |
| 52-Week Low | 4.8 |
| Volume | 922,189 |
| Average Volume | 1.45M |
| Market Cap | 446.92M |
| PE | -2.14 |
| EPS | -4.73 |
| Moving Average 50 Days | 10.12 |
| Moving Average 200 Days | 8.23 |
| Change | 0 |
If you invested $1000 in iTeos Therapeutics, Inc. (ITOS) since IPO date, it would be worth $530.71 as of August 18, 2025 at a share price of $10.11. Whereas If you bought $1000 worth of iTeos Therapeutics, Inc. (ITOS) shares 3 years ago, it would be worth $434.84 as of August 18, 2025 at a share price of $10.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
GlobeNewswire Inc.
Jul 21, 2025 11:29 AM GMT
WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (“iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) wil
iTeos Therapeutics Announces Its Intention to Wind Down Operations
GlobeNewswire Inc.
May 28, 2025 12:30 PM GMT
- Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215, and a preclinical obesity program targeting EN
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
GlobeNewswire Inc.
May 13, 2025 11:55 AM GMT
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a